โรคฮีโมฟีเลีย

Stonebraker JS, Bolton-Maggs PHB, Brooker M, Evatt B, Iorio A, Makris M, et al. The World Federation of Hemophilia Annual Global Survey 1999-2018. Haemophilia. 2020;26:591-600.

Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020:26(Suppl 6):1-158.

Gouider E. Show me the evidence: effectiveness of low-dose prophylaxis. Haemophilia. 2020;26(Suppl 3):9-10.

Chuansumrit A, Sosothikul D, Natesirinilkul R, Lektrakul Y, Charoonruangrit U; Factor VIII Study Group. Efficacy and safety of low-dose prophylaxis of highly purified plasma-derived factor VIII concentrate produced by the National Blood Centre, Thai Red Cross Society. Haemophilia. 2018;24:e387-90.

Jimenez-Yuste V, Auerswald G, Benson G, Dolan G, Hermans C, Lambert T, et al. Practical considerations for nonfactor-replacement therapies in the treatment of haemophilia with inhibitors. Haemophilia. 2021;27:340-50.

Narkbunnam N, Krittiwattanapong K, Bunnun J, Pongtanakul B. Comparing quality of life of prophylaxis versus on demand treatment among patients with hemophilia at Siriraj hospital. J Hematol Transfus Med. 2022;32:219-26.

Usuba K, Price VE, Blanchette V, Abad A, Altisent C, Buchner-Daley L, et al. Impact of prophylaxis on health-related quality of life of boys with hemophilia: an analysis of pooled data from 9 countries. Res Pract Thromb Haemost. 2019;3:397-404.

Deepijarn N, Chariyavilaskul P, Na Songkhla P, Kanchanakamhaeng K, Sosothikul D. Pharmacokinetics of recombinant factor VIII in pediatric patients with hemophilia A, a multicenter study in Thailand. J Hematol Transfus Med. 2022;32:227-33.

Chen ZP, Li PJ, Li G, Tang L, Zhen YZ, Wu XY, et al. Pharmacokinetic studies of factor VIII in Chinese boys with severe hemophilia A: a single-center study. Chin Med J (Engl). 2018;131:1780-5.

Chuansumrit A,Panuwannakorn M, Jaovisidha S, Jiravichitchai T, Kempka K, Sasanakul W, et al. The Beneficial Effect of Prophylactic Emicizumab on Thai Hemophilia A with and without Inhibitor: A Case Series Report. J Hematol Transfus Med. 2022;32:235-44.

Callaghan MU, Negrier C, Paz-Priel I, Chang T, Chebon S, Lehel M, et al. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood. 2021;137:2231-42.